News & Updates

Temporary interruption of adjuvant endocrine therapy (ET) to allow for pregnancy has demonstrated short-term safety, with no increase in risk of breast cancer events, including distant recurrence, in hormone receptor–positive breast cancer survivors who have completed 18–30 months of adjuvant ET.

Low skeletal muscle mass accompanied by abdominal obesity is significantly associated with a higher risk of incident type 2 diabetes (T2D), irrespective of the glycometabolic parameters, reveals a study.

The incidence of melanoma and nonmelanoma skin cancer appears to be markedly low among people with vitiligo, as reported in a study.